GRI Bio, Inc.
NASDAQ: GRI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- W. Marc Hertz
- Employees
- 4
- Headquarters
- La Jolla, United States
- IPO year
- 2021
- Market cap
- $165.3K
- Website
- https://www.gribio.com
Loading GRI…
Loading profile data…Frequently asked questions about GRI
What does GRI Bio, Inc. (GRI) do?
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clini...
Where does GRI trade?
GRI Bio, Inc. (GRI) trades on the NASDAQ.
What sector is GRI in?
GRI Bio, Inc. (GRI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of GRI Bio, Inc.?
W. Marc Hertz is the chief executive officer of GRI Bio, Inc. (GRI).
Where is GRI Bio, Inc. headquartered?
GRI Bio, Inc. is headquartered in United States.
Does GRI pay a dividend?
GRI Bio, Inc. (GRI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GRI go public?
GRI Bio, Inc. (GRI) completed its initial public offering in 2021.